AbbVie (NYSE:ABBV) Stock Keeps “Buy” Rating at Guggenheim

AbbVie (NYSE:ABBV)‘s stock had its “buy” rating reaffirmed by equities research analysts at Guggenheim in a report issued on Friday, Benzinga reports. They presently have a $288.00 price target on the stock. Guggenheim’s target price indicates a potential upside of 4.70% from the stock’s previous close.

Other equities research analysts have also issued research reports about the stock. Piper Sandler lifted their target price on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Bank of America reiterated a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Canaccord Genuity Group boosted their price target on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. BMO Capital Markets raised their price target on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Finally, Morgan Stanley upped their price target on shares of AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $277.18.

AbbVie Stock Performance

NYSE ABBV traded up $2.65 on Friday, hitting $275.07. 655,703 shares of the stock traded hands, compared to its average volume of 6,399,344. AbbVie has a 12 month low of $190.75 and a 12 month high of $276.61. The firm has a market capitalization of $485.99 billion, a price-to-earnings ratio of 77.79, a PEG ratio of 1.23 and a beta of 0.24. The business’s fifty day moving average is $258.56 and its two-hundred day moving average is $236.35.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the prior year, the business earned $2.97 earnings per share. AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts expect that AbbVie will post 14.01 EPS for the current fiscal year.

Insider Activity at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by insiders.

Institutional Investors Weigh In On AbbVie

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABBV. Burk Holdings LLC acquired a new position in shares of AbbVie during the 2nd quarter valued at about $30,000. Abound Financial LLC purchased a new stake in AbbVie in the fourth quarter valued at approximately $32,000. Merkkuri Wealth Advisors LLC purchased a new position in AbbVie during the 1st quarter valued at about $34,000. Marquette Asset Management LLC increased its stake in AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after buying an additional 48 shares during the period. Finally, Phillip James Consulting Co. purchased a new stake in shares of AbbVie during the fourth quarter worth $36,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts raised targets and reaffirmed bullish ratings. Guggenheim reaffirmed its “buy” rating with a $288 price target, while JPMorgan raised its target to $300 and maintained an “overweight” rating. Cantor Fitzgerald also lifted its target to $290 and kept an “overweight” rating. The revisions indicate continued confidence in AbbVie’s earnings outlook and growth prospects.
• Positive Sentiment: Temab-A received two FDA Breakthrough Therapy Designations. AbbVie’s telisotuzumab adizutecan (Temab-A, or ABBV-400) received the designations for potential use in colorectal cancer and non-small cell lung cancer. The FDA status may accelerate development and review, strengthening the perceived value of AbbVie’s oncology pipeline. FDA Grants Breakthrough Therapy Designations to AbbVie’s Temab-A
• Positive Sentiment: Additional oncology data supported pipeline optimism. An AbbVie and Genmab combination involving epcoritamab reportedly reduced the risk of progression or death by 51% in diffuse large B-cell lymphoma, providing another favorable signal for AbbVie’s cancer portfolio.
• Positive Sentiment: Momentum has pushed ABBV to new one-year highs. The stock recently set consecutive 52-week highs, suggesting that analyst upgrades and pipeline news are reinforcing positive investor sentiment.
• Neutral Sentiment: Valuation and expectations remain important risks. AbbVie is trading near its 12-month high with a relatively elevated price-to-earnings ratio, so further gains may depend on the company delivering against strong earnings and pipeline expectations. Recent coverage also noted mixed growth outlooks across large pharmaceutical companies, despite higher price targets.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.